Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments by conveying synthetic immunity to patients."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments by conveying synthetic immunity to patients."> <meta property="og:title" content="Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape"> <meta name="twitter:description" content="Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments by conveying synthetic immunity to patients."> <meta name="twitter:title" content="Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/nextgen-biomed/resources/bispecific-t-cell-engagers-and-synthetic-immunity-circumventing-immune-escape"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/Bispecific-T-Cell-Engagers-Synthetic-Immunity-Halting-Immune-Escape-rotated.jpg"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/Bispecific-T-Cell-Engagers-Synthetic-Immunity-Halting-Immune-Escape-rotated.jpg"> <meta property="og:url" content="https://oxfordglobal.com/nextgen-biomed/resources/bispecific-t-cell-engagers-and-synthetic-immunity-circumventing-immune-escape"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="nextgen-biomed"> <div class="body-wrapper hs-content-id-177607186815 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/nextgen-biomed" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/nextgen-biomed/events/nextgen-biomed-2025" class="pill center"> <div class="b">NextGen Biomed 2025</div> <div class="heading-smallcaps"> 12 - 14 Mar 2025 | London, UK </div> </a> <a href="/nextgen-biomed/events/cell-2025" class="pill center"> <div class="b">Cell 2025</div> <div class="heading-smallcaps"> 11-12 Nov 2025 | London, UK </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing" class="cta" target="_blank"> <h3 class="other-resources">01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in from nextgen biomed research & development</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All NextGen Biomed Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus">University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus</a> </h3> <div class="resource-abstract"> <span class="resource-date">08/11/24 - </span> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants">07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine">31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine</a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/nextgen-biomed/resources/sponsored/webinar/wuxibiologics/sp-webinar-optimizing-bispecific-antibody-production-from-identifying-optimal-pairings-to-scale-up-processes"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Digital%20Marketing/Webinars/Email%20and%20Social%20Collateral/NGB%20-%20Wuxi%20Biologics/WuXi%20Biologics.png" class="sponsor-resource-cover-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes </h3> <div class="resource-abstract"> On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Drug Discovery & Development | Industry Spotlights & Insight Articles </div> <h1 class="heading"> Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape </h1> <div class="byline"> 30 September 2022 </div> <div class="abstract"> Synthetic immunity mediated by bispecific T Cell engagers may help to bypass immune escape posed by a lack of appropriate immunotherapeutic target expression. Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments, with the potential to become off-the-shelf therapeutics. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/Bispecific-T-Cell-Engagers-Synthetic-Immunity-Halting-Immune-Escape-rotated.jpg" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap"> <p></p> <p>Presented by: <strong>Genevive Hernandez</strong>, Senior Director and Head of Clinical Biomarkers at IGM Biosciences</p> <p></p> <p></p> <p>Edited by: <strong>Ben Norris</strong></p> <p></p> <p></p> <p>A serious obstacle in the treatment of cancers involves immune escape. Bispecific T cell engagers (TCEs) have been developed to mitigate this issue, forming a key aspect of the body's anti-cancer response. For Genevive Hernandez, Senior Director and Head of Clinical Biomarkers at IGM Biosciences, the aim is to convert non-specific endogenous T cells into synthetic anti-tumoural effectors. In achieving this, IGM Bio can work towards a longer-term goal of providing off-the-shelf therapies for cancer treatment and immunotherapy, with the end goal of synthetic immunity.</p> <p></p> <p></p> <h2 id="h-circumventing-issues-around-synthetic-immunity"><strong>Circumventing Issues Around Synthetic Immunity</strong></h2> <p></p> <p></p> <p>Genevive Hernandez’s presentation at <strong>Preclinical Immuno-Oncology 2022</strong> began by touching on the different processes involved in the generation of endogenous, anti-cancerous T-cell-mediated immune responses. “There are various mechanisms which can limit each of these steps,” she opened. “These include the lack of an immunogenic tumour antigen, improper antigen presentation, no tumour-specific cells, or a low frequency of these cells.”</p> <p></p> <p></p> <ul> <li><a href="https://www.oxfordglobal.co.uk/resources/the-challenges-facing-antibody-drug-conjugates-for-immuno-oncology/" target="_blank" rel="noreferrer noopener">The Main Challenges Facing Antibody-Drug Conjugates</a></li> <li><a href="https://www.oxfordglobal.co.uk/resources/express-your-cells-enhancing-t-cell-function-with-small-molecule-hpk1-inhibitors/" target="_blank" rel="noreferrer noopener">Enhancing T Cell Function with Small Molecule HPK1 Inhibitors: Express Your Cells</a></li> <li><a href="https://www.oxfordglobal.co.uk/resources/inkt-cells-and-their-applications-in-immuno-oncology/" target="_blank" rel="noreferrer noopener">The Applications of iNKT Cells in Immuno-Oncology</a></li> </ul> <p></p> <p></p> <p>Additional complications can arise from the inhibition of T cell infiltration by tumour stroma, an immunosuppressive tumour microenvironment, and downregulation or loss of the major histocompatibility complex (MHC). Synthetic immunity is the means by which endogenous immune responses can be reprogrammed. “The idea behind synthetic immunity is to bypass these critical limitations and leverage the full repertoire of T cell syndication in order to kill cancer cells,” continued Hernandez.</p> <p></p>  <p>There are two major approaches for inducing synthetic immunity: the first involves the transfer of T cells which have been genetically modified <em>ex vivo</em> to express Chimeric Antigen Receptors, better known as CAR-T cells. The second method concerns bispecific T cell engagers (TCEs). These methods are being piloted to assist in confronting immune escape — an immune scenario where new mutations of a particular pathogen may evade human antibodies.</p>   <h2><strong>Synthetic Immunity with Bispecific T Cell Engagers</strong><strong></strong></h2>   <p>As Hernandez explained, the goal with TCEs is to convert non-specific endogenous T cells into potent ‘synthetic’ anti-tumour effectors targeted at tumour-associated antigens (TAA). These are conditional, agonist recombinant antibodies, which are independent of both MHC and TCR. The aim of their application is to convert immune ‘cold’ to immune ‘hot’ tumours, with the end goal of providing off-the-shelf therapy with broad applicability and usage beyond transplant centres.</p>   <figure class="wp-block-image size-full is-resized"><img src="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/Bispecific-TCE-Platforms.jpg?width=840&height=840&name=Bispecific-TCE-Platforms.jpg" alt="Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments by conveying synthetic immunity to patients." class="wp-image-32843" width="840" height="840" srcset="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/Bispecific-TCE-Platforms.jpg?width=420&height=420&name=Bispecific-TCE-Platforms.jpg 420w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/Bispecific-TCE-Platforms.jpg?width=840&height=840&name=Bispecific-TCE-Platforms.jpg 840w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/Bispecific-TCE-Platforms.jpg?width=1260&height=1260&name=Bispecific-TCE-Platforms.jpg 1260w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/Bispecific-TCE-Platforms.jpg?width=1680&height=1680&name=Bispecific-TCE-Platforms.jpg 1680w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/Bispecific-TCE-Platforms.jpg?width=2100&height=2100&name=Bispecific-TCE-Platforms.jpg 2100w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Immuno/Bispecific-TCE-Platforms.jpg?width=2520&height=2520&name=Bispecific-TCE-Platforms.jpg 2520w" sizes="(max-width: 840px) 100vw, 840px"><figcaption><strong><em>Figure 1.</em></strong><em> The functionality and form of bispecific T cell engager platforms.</em></figcaption></figure>   <p></p>   <p>A major focus for Hernandez is bispecific TCE derived from recombinant antibodies. As the name denotes, these bispecific TCEs have two specificities: one is to a tumour-associated antigen expressed on the target’s cell surface, and the other is CD3 expressed on the T cell. “They act as a conditional agonist in an MHC, TCR and post-simulation independent fashion,” said Hernandez, “leading to a chance for the alteration of T cell specificity.” This subsequently triggers the conversion of non-specific endogenous T cells into potent, synthetic anti-tumour effectors that directly kill tumour cells.</p>   <p>At the time of Hernandez’s presentation, one TCE has been cleared for clinical use: blinatumomab, which was approved by the FDA in 2014 for the B cell precursor ALL. There are over 50 TCEs currently in clinical development worldwide, although right now the market is still maturing. The properties of antibodies concerned with TCEs can differ depending on characteristics such as valency and symmetry.</p>   <h2><strong>CD20xCD3 TCE Biomarkers Based on Mechanism of Action</strong><strong></strong></h2>   <p>Focusing on the specific example of CD20xCD3 TCE, Hernandez discussed some of the traits of these treatment methods in pre-clinical and clinical studies. TCE stimulation results in the activation of biomarkers CD69 and CD25, along with HLA-DR. This leads to T cell proliferation and secretion of cytokines, as well as the infiltration of T cells into tumour tissue. Hernandez emphasised that the quality and quantity of T cells is key, with a strong and rapid activation required from TCE for early tumour cell clearance. However, if the activation is too strong then this can lead to acute safety consequences, and this may result in a loss of T cell responsiveness.</p>   <p>With tumour cells, antigen expression is necessary but not always sufficient: proliferative status and susceptibility to apoptosis may counteract T cell cytotoxicity. At the same time, T cells need to be in the right location to function effectively. Biomarker data for bispecific TCEs shows that there may be many benefits for these drugs, with evidence that the number, location, and functionality of T cells may all be critical.</p>   <h2><strong>Next Generation Bispecific TCE: Engineered IgM Antibodies</strong></h2>   <p>Hernandez stated that one next generation approach to enable several levels of controlling TCE activity involves engineered IgM-based TCE that can bind irreversibly to cancer cells. “Because of the biophysical, stoichiometric and temporal features of this platform, we hypothesise that it can deliver a more physiological signal to T cells that also limits over-stimulation.” IGM-2323 (imvotamab) is a novel CD20xCD3 TCE with 10 high-affinity, high-avidity binding sites to CD20 and a single binding site to CD3 designed to enhance immune modulation. </p>   <p>IGM-2323 provides T cell-dependent and complement-dependent killing of cancer cells, and subsequently leads to repeatable IFN?? dominant immune action. “Importantly, IGM-2323 may limit the supraphysiologic stimulation of T cells,” she added. Its application may provide more physiologic T cell activation compared with existing T cell-engaging antibodies, and T cells respond differently to variable levels of TCR signalling. This leads to the secretion of more physiologic levels of cytokines, improving their safety and tolerability.</p>   <h2><strong>Synthetic Immunity Takeaways</strong><strong></strong></h2>   <p>Hernandez rounded off her presentation by emphasising some of the main takeaways for bispecific TCEs in terms of their applications. Synthetic immunity mediated by bispecific TCEs may help to bypass immune escape posed by a lack of appropriate immunotherapeutic target expression, MHC loss, and multiple layers of T cell regeneration by generating the potent T cell-based killing of cancer cells.</p>   <p>Some of the biggest challenges for the further development and implementation of bispecific TCEs include cytokine release syndrome (CRS), target expression levels, T cell function in the tumour microenvironment, and its impact on endogenous immunity in the host. As Hernandez explained, bispecific TCE activity can be monitored through select host biomarkers. Based on the mechanism of action (MOA), biomarker behaviour can inform the selection of dose and schedule, the mitigation of safety risks, and the enhancement of efficacy. </p>   <p>Hernandez thanked her colleagues at IGM Biosciences for their work on IGM-2323 (imvotamab), as well as the patients, caregivers, investigators, and nurses for their studies.</p>   <p><em>Want to read more about new advances in immuno-oncology and ongoing immune therapies? </em><a href="https://oxfordglobal.com/immuno/" target="_blank" rel="noreferrer noopener"><em>Visit our Immuno portal</em></a><em> to find current insights from the industry’s best and brightest. If you’d like to register your interest in our upcoming Tumour Microenvironment: In-Person conference, </em><a href="https://oxfordglobal.com/tumour-microenvironment/" target="_blank" rel="noreferrer noopener"><em>visit our event website</em></a><em>.</em></p>  <div class="content-body-footer"> <div class="author-info text-no-gap"> <div class="author-about"> <h3> Speaker Biographies </h3> <p>Genevive Hernandez-Pantua is Senior Director and Head of Clinical Biomarkers at IGM Biosciences, a biotechnology company pioneering the use of novel engineered multivalent and multispecific therapeutics. She was previously at Genentech, where she completed her postdoctoral studies on the interplay between angiogenesis and tumour immunity, and then became the Biomarker Lead for multiple trials of the breakthrough cancer immunotherapies atezolizumab (anti-PDL1 Ab) and mosunetuzumab (CD20xCD3 bispecific Ab).</p> </div> </div> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/nextgen-biomed/resources/t-cell-engagement-and-activation-new-developments"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/T-Cell-Engagement-and-Activation-New-Developments.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/t-cell-engagement-and-activation-new-developments"> <h4> T Cell Engagement and Activation: New Developments </h4> <div class="abstract"> As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/t-cell-engagement-and-activation-new-developments" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/harnessing-bispecific-t-cell-engagers-and-t-cell-primers-in-cancer-treatment"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Bispecific-T-Cell-Engagers-and-Primers-scaled.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/harnessing-bispecific-t-cell-engagers-and-t-cell-primers-in-cancer-treatment"> <h4> Harnessing Bispecific T Cell Engagers and T Cell Primers in Cancer Treatment </h4> <div class="abstract"> Stimulating T cells using bispecific antibody immunotherapies can lead to transformational clinical benefits for cancer patients. So how exactly is the industry addressing the need for targeted T cell-based immunotherapies? </div> <div class="read-more"> <a href="/nextgen-biomed/resources/harnessing-bispecific-t-cell-engagers-and-t-cell-primers-in-cancer-treatment" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things NextGen Biomed </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177053686099">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/nextgen-biomed\/resources\/bispecific-t-cell-engagers-and-synthetic-immunity-circumventing-immune-escape"]); _hsq.push(["setPageId", "hubdb-177607186815-30817717-181072999428"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177607186815-30817717-181072999428", "legacyPageId": "hubdb-177607186815-30817717-181072999428", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177607186815, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "af845689-2d29-4562-87a9-d0e2cf1430c3", ticks: 1732694819638, page_id: 177607186815, dynamic_page_id: "hubdb-177607186815-30817717-181072999428", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177607186815-30817717-181072999428", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape